Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
 Rebranding and Consolidating BioMarin’s Comprehensive Support and Services for Eligible Rare Disease Patients - EconoTimes)
SAN RAFAEL, Calif., Feb. 29, 2016 -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the launch of BioMarin RareConnectionsTM, rebranding its patient-focused offering formally known as the BioMarin Patient and Physician Support (BPPS). For over 10 years, BioMarin has been a leader in designing and implementing multiple separate service offerings to support our patients. With the launch of BioMarin RareConnections, it now provides them under one expanded program, which includes clinical support for eligible patients throughout treatment and assistance to gain and maintain access to BioMarin’s innovative therapies.
BioMarin RareConnections offers personalized assistance to patients in the United States, who have been prescribed or are considering a BioMarin therapy for Morquio A, MPS VI and phenylketonuria (PKU), and their caregivers. While specific services will vary by medication, BioMarin RareConnections support includes access to dedicated case managers and clinical coordinators, as well as help securing insurance coverage and/or financial assistance. Additional services may include coordination of medication deliveries and disease and product education.
“Patients and their families battling rare conditions face uncommon challenges. As a leader in the community, it is our responsibility to provide unparalleled support to help ensure our patients, who are eligible for BioMarin approved therapies, have access to, and are connected with, the exceptional care they deserve,” said Jeff Ajer, Chief Commercial Officer of BioMarin. “We are proud that BioMarin RareConnections will house all of our support services in one area to help us serve as a trusted partner in care.”
To learn more about BioMarin RareConnections, call 1-866-906-6100 or email [email protected].
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.
Contact: Investors: Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media: Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
